Clinical TrialsPositive data from the Sezary syndrome (SS) cohort of the study, with a global ORR of 37.5%, fuels optimism that the combination therapy could deliver meaningful clinical benefit.
Financial HealthCompany has sufficient cash to fund operations through 2025, providing stability and support for ongoing research and development activities.
Research And DevelopmentPreclinical data with IPH45 shows promise as an effective ADC with a high drug-antibody-ratio (DAR) of 8, suggesting a potential for strong therapeutic effect.